Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Harry M. Meade
Advertisement
Harry M. Meade, PhD, is senior vice president of research and development at GTC Biotherapeutics, Inc.
Articles by Harry M. Meade
Advertisement
Latest Updated Articles
Production of Recombinant Therapeutic Proteins in the Milk of Transgenic AnimalsPublished: August 1st 2006 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Trends in Formulation eBook October 2025
2
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
3
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
4
Analytics, Automation, and Quality Driving the Next Era of Drug Development
5
